Evommune, Inc. filed an 8-K on September 9, 2026, disclosing that its Phase 2b trial of EVO756 in adults with moderate-to-severe atopic dermatitis did not meet its primary or secondary endpoints at any dose studied, and that the company plans to cease development of EVO756 for that indication.

Key Highlights

  • Trial failed all endpoints: The Phase 2b trial "did not meet the primary and secondary endpoints in any of the doses studied," according to the filing.
  • 121 adults enrolled: The randomized, double-blind, placebo-controlled, dose-ranging trial enrolled 121 adults over a 12-week treatment period, with follow-up through Week 14.
  • EVO756 development in AD to cease: The company disclosed it plans to cease development of EVO756 for atopic dermatitis based on the Phase 2b results.
  • Migraine prophylaxis evaluation continues: The company stated it will continue to evaluate EVO756 in migraine prophylaxis.
  • Cash runway extended into 2029: Based on revised clinical development plans, the company expects its current cash, cash equivalents, and investments to fund operations into 2029.
  • Emerging growth company: Evommune is designated an emerging growth company under applicable SEC rules, as indicated on the filing's cover page.

Evommune Discloses EVO756 Phase 2b Failure and Revised Development Plans

Evommune, Inc. (NYSE:EVMN), a Palo Alto, California-based biopharmaceutical company, issued a press release on September 8, 2026, announcing top-line results from its Phase 2b trial of EVO756, an oral MRGPRX2 antagonist, in adults with moderate-to-severe atopic dermatitis. The trial was randomized, double-blind, placebo-controlled, and dose-ranging. According to the filing, the trial enrolled 121 adults and ran for a 12-week treatment period, with follow-up extending through Week 14.

The company disclosed that the trial "did not meet the primary and secondary endpoints in any of the doses studied." As a direct result, the company reported it plans to cease development of EVO756 for atopic dermatitis. The filing noted, however, that Evommune "will continue to evaluate EVO756 in migraine prophylaxis," which is characterized in the filing as a forward-looking statement subject to the cautionary language of the Private Securities Litigation Reform Act of 1995.

Alongside the clinical update, the filing disclosed a financial runway statement: based on current business plans, including the revised clinical development plans described in the accompanying press release, the company expects its current cash, cash equivalents, and investments to be sufficient to fund operations into 2029. This statement was also identified in the filing as forward-looking and subject to various risk factors described in the company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC. The press release, attached as Exhibit 99.1, was furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

What Was Disclosed

Evommune filed an 8-K reporting that its EVO756 Phase 2b trial in moderate-to-severe atopic dermatitis failed to meet any primary or secondary endpoints across all doses, leading the company to plan cessation of that program while continuing to explore EVO756 in migraine prophylaxis.